other material
confidence high
sentiment positive
materiality 0.65
Gain Therapeutics' rexaceract holds MDS-UPDRS scores stable over 12 months; Phase 2 in Parkinson's set for Q1 2027
Gain Therapeutics, Inc.
- 12 of 13 evaluable patients completed the full 12-month rexaceract dosing in the Phase 1b open-label extension; one remaining participant finishes in November 2026.
- MDS-UPDRS Parts II+III motor scores remained stable over 360 days, versus the ~6-point annual increase generally accepted as clinically meaningful PD progression.
- Company expects to submit a new Phase 2 protocol to the FDA in coming weeks and initiate the Phase 2 trial in people with Parkinson's disease in Q1 2027.
- No new safety signals over 12 months; a lower incidence of treatment-emergent adverse events occurred in the nine-month extension (Part 2) than in the initial three-month dosing (Part 1).
- High and low baseline CSF GluSph patients both showed stable motor scores at 12 months; high-baseline patients had large GluSph drops toward healthy levels by day 90 and faster response.